BiotechTube

NDX-1017 + Placebo

Phase 1Completed
0 watching 0 views this week💤 Quiet
25
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Alzheimer Disease

Conditions

Alzheimer Disease

Trial Timeline

Oct 9, 2017 → Sep 5, 2019

NCT ID
NCT03298672

About NDX-1017 + Placebo

NDX-1017 + Placebo is a phase 1 stage product being developed by LeonaBio for Alzheimer Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT03298672. Target conditions include Alzheimer Disease.

Hype Score Breakdown

Clinical
10
Activity
5
Company
2
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT03298672Phase 1Completed

Competing Products

20 competing products in Alzheimer Disease

See all competitors
ProductCompanyStageHype Score
[18F]NAV4694Navidea BiopharmaceuticalsPhase 2
44
Bromocriptine Mesilate + PlacebosTowa PharmaceuticalPhase 1/2
40
LY450139 + PlaceboEli LillyPhase 3
77
Solanezumab + PlaceboEli LillyPhase 3
77
LY450139 dihydrate + placeboEli LillyPhase 2
52
Zagotenemab + PlaceboEli LillyPhase 2
52
Donanemab + Placebo + LY3202626Eli LillyPhase 2
52
Donanemab + PlaceboEli LillyPhase 3
77
GSK4527226AlectorPhase 2
44
AL002 + PlaceboAlectorPhase 2
44
GSK4527226AlectorPhase 2
44
AL002AlectorPhase 2
44
Solanezumab + PlaceboEli LillyPhase 3
77
donanemabEli LillyPhase 2
52
ATH-1017LeonaBioPhase 2/3
57
ATH-1017 + PlaceboLeonaBioPhase 2/3
57
ATH-1017 + PlaceboLeonaBioPhase 2
44
simufilamCassava SciencesPhase 2
44
50 mg PTI-125 + 100 mg PTI-125 + 200 mg PTI-125Cassava SciencesPhase 1
25
Placebo oral tablet + Simufilam 100 mg tablet + Simufilam 50 mg oral tabletCassava SciencesPhase 2
44

Other Products from LeonaBio

ATH-1017Phase 2/3
57
ATH-1017 + PlaceboPhase 2/3
57
ATH-1017 + PlaceboPhase 2
44
ATH-1017 + PlaceboPhase 2
44
ATH-1105 + PlaceboPhase 1
25